Among the detected pathways, we identified pathways that could represent potential targets for treatment of subgroups of leiomyosarcoma patients, including RB1/E2F1 signaling, pathways involved in FGFR signaling, and CTLA4 inhibitory signaling. This evidence concerns the gene E2F1 and leiomyosarcoma.